Fiera Capital Corp Reduces Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Fiera Capital Corp trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.1% in the second quarter, Holdings Channel.com reports. The firm owned 357,975 shares of the company’s stock after selling 11,392 shares during the period. Fiera Capital Corp’s holdings in Neurocrine Biosciences were worth $33,757,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Raymond James Financial Services Advisors Inc. raised its stake in Neurocrine Biosciences by 0.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 14,526 shares of the company’s stock worth $1,370,000 after acquiring an additional 104 shares during the period. First Republic Investment Management Inc. lifted its stake in Neurocrine Biosciences by 1.0% in the fourth quarter. First Republic Investment Management Inc. now owns 11,069 shares of the company’s stock valued at $1,322,000 after buying an additional 113 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. lifted its stake in Neurocrine Biosciences by 1.9% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,430 shares of the company’s stock valued at $627,000 after buying an additional 120 shares during the last quarter. CWM LLC boosted its holdings in shares of Neurocrine Biosciences by 10.1% during the second quarter. CWM LLC now owns 1,385 shares of the company’s stock valued at $131,000 after acquiring an additional 127 shares during the period. Finally, Linden Thomas Advisory Services LLC grew its position in shares of Neurocrine Biosciences by 0.9% during the second quarter. Linden Thomas Advisory Services LLC now owns 15,533 shares of the company’s stock worth $1,465,000 after acquiring an additional 138 shares during the last quarter. Hedge funds and other institutional investors own 93.54% of the company’s stock.

Insider Activity at Neurocrine Biosciences

In related news, insider David W. Boyer sold 2,733 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $107.60, for a total transaction of $294,070.80. Following the transaction, the insider now owns 3,460 shares of the company’s stock, valued at $372,296. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider David W. Boyer sold 2,733 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $107.60, for a total value of $294,070.80. Following the completion of the sale, the insider now directly owns 3,460 shares in the company, valued at $372,296. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jude Onyia sold 3,198 shares of the firm’s stock in a transaction on Monday, August 21st. The shares were sold at an average price of $107.37, for a total transaction of $343,369.26. Following the completion of the transaction, the insider now owns 9,638 shares in the company, valued at $1,034,832.06. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,083 shares of company stock valued at $3,400,811. 4.60% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Up 2.9 %

Shares of NASDAQ:NBIX opened at $110.25 on Tuesday. Neurocrine Biosciences, Inc. has a 12-month low of $89.04 and a 12-month high of $129.29. The firm has a market capitalization of $10.83 billion, a P/E ratio of 59.27, a price-to-earnings-growth ratio of 1.01 and a beta of 0.40. The firm has a fifty day moving average of $112.09 and a two-hundred day moving average of $103.38.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Tuesday, October 31st. The company reported $0.82 EPS for the quarter, missing analysts’ consensus estimates of $0.91 by ($0.09). Neurocrine Biosciences had a net margin of 10.71% and a return on equity of 10.54%. The firm had revenue of $498.80 million during the quarter, compared to analysts’ expectations of $479.09 million. During the same quarter last year, the firm earned $0.69 EPS. The business’s revenue for the quarter was up 28.6% compared to the same quarter last year. Equities research analysts expect that Neurocrine Biosciences, Inc. will post 2.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Neurocrine Biosciences in a research report on Tuesday, October 24th. Barclays lifted their price target on Neurocrine Biosciences from $125.00 to $134.00 in a report on Thursday, September 21st. BMO Capital Markets decreased their price objective on Neurocrine Biosciences from $111.00 to $100.00 and set a “market perform” rating for the company in a report on Friday. SVB Securities raised Neurocrine Biosciences from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $115.00 to $125.00 in a research note on Monday, July 24th. Finally, HC Wainwright boosted their price target on Neurocrine Biosciences from $146.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, October 6th. Five investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $131.46.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.